NCT00242762View on ClinicalTrials.gov

ZD1839 (IRESSA™) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions
Head and Neck Cancer
Interventions
DRUG

ZD1839 (IRESSA™)

DRUG

Docetaxel

DRUG

Cisplatin

Trial Locations (4)

Unknown

Research Facility, Granada

Research Facility, Madrid

Research Facility, Murcia

Research Site, Seville

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY